儿童门肺高压在现代管理时代的结局:6例病例报告
该病例系列描述了6例儿童门肺高压患者的诊治经验,诊断中位年龄13岁,中位平均肺动脉压47 mmHg,中位肺血管阻力6.6 Wood单位。除一例外均接受肺动脉高压靶向联合治疗,3例随后行分流关闭术,其余行肝移植;平均随访39个月,5例改善或稳定,无死亡。
要点
- 儿童门肺高压诊断时肺动脉压和肺血管阻力常显著升高。
- 肺动脉高压靶向联合治疗可改善血流动力学并桥接肝移植或分流关闭。
- 本系列平均随访39个月无死亡,但样本量小需谨慎解读。
核心结论
- 基于有限经验,早期积极使用肺动脉高压靶向联合治疗可显著改善患儿血流动力学,并使肝移植和分流关闭得以实施且结局满意。
研究设计与样本
- 单中心真实世界病例系列,纳入6例儿童门肺高压患者。
主要发现
- 诊断中位年龄13岁(范围10-15岁)。
- 中位平均肺动脉压47 mmHg(范围32-70),中位肺血管阻力6.6 Wood单位(范围4.3-15.4)。
- 除一例外均接受肺动脉高压靶向联合治疗(磷酸二酯酶5抑制剂和/或内皮素受体拮抗剂和/或前列环素类似物)。
- 3例随后行分流关闭术,其余行肝移植;平均随访39个月,5例改善或稳定,无死亡。
临床怎么用
- 对儿童门肺高压应早期积极联合肺动脉高压靶向治疗,以改善血流动力学并创造肝移植或分流关闭条件。
局限性
- 样本量小(6例),为单中心经验,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Portopulmonary hypertension is a rare but serious complication of portal hypertension or portosystemic shunting. Portopulmonary hypertension is an indication for liver transplantation or shunt closure. However, liver transplantation is contraindicated in patients with severe pulmonary arterial hypertension. Reported mortality rates are high in children with portopulmonary hypertension and there are scarce recommendations on its management. Our aim was to report on our real-world experience of managing portopulmonary hypertension in a specialised centre. We describe a series of 6 children with portopulmonary hypertension. Their median age at diagnosis was 13 years (range 10-15). The underlying liver conditions were cirrhosis of unknown origin (1), congenital portocaval shunts (3), biliary atresia (1), and portal vein cavernoma with surgical mesenterico-caval shunt (1). Median mean pulmonary arterial pressure was 47 mmHg (range 32-70), and median pulmonary vascular resistance was 6.6 Wood units (range 4.3-15.4). All patients except one were treated with a combination of pulmonary arterial hypertension-specific therapy (phosphodiesterase type 5 inhibitors and/or endothelin receptor antagonists and/or prostacyclin analogues). Three patients then benefited from shunt closure and the others underwent liver transplantation. Five patients showed improvement or stabilisation of pulmonary arterial hypertension with no deaths after a mean follow-up of 39 months. Based on our limited experience, early and aggressive treatment with a combination of pulmonary arterial hypertension-specific therapy significantly improves patients' haemodynamic profile and enables the performance of liver transplantation and shunt closure with satisfactory outcomes.
引用
- Joye R, Lador F, Aggoun Y, et al. Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients. J Hepatol. 2020. PMID: 33276028. doi:10.1016/j.jhep.2020.11.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。